CN104876899A

CN104876899A - Dimethylamino sphaelactone fumarate and use thereof

Info

Publication number: CN104876899A
Application number: CN201410071673.6A
Authority: CN
Inventors: 邱传将; 齐杰; 王桂燕
Original assignee: Accendatech Co Ltd
Current assignee: Accendatech Co Ltd
Priority date: 2014-02-28
Filing date: 2014-02-28
Publication date: 2015-09-02

Abstract

The invention relates to a compound represented by formula (I), that is, dimethylamino sphaelactone fumarate, and a use thereof. The compound of formula (I) has the advantages of high stability and low hygroscopicity.

Description

Dimethylamine has a smile on one's face lactone fumarate and uses thereof

Technical field

The invention belongs to technical field of pharmaceuticals, be specifically related to dimethylamine and have a smile on one's face lactone fumarate and uses thereof.

Background technology

Document (J. Med. Chem. 2012,55,8757 8769) in, report formula II compound is used for the treatment of leukemia, but further research find formula II compound exist unstable, draw the moist defect such as seriously, limit its further medicament research and development.

（Ⅱ）

Compound provided by the invention overcome formula II compound exist unstable, draw the moist defect such as seriously, have stability high, draw moist low advantage.

Summary of the invention

The invention provides formula I compound, dimethylamine has a smile on one's face lactone fumarate and uses thereof.

(Ⅰ)

Described formula I compound is being used for the treatment of the purposes in cancer.Wherein said cancer comprises acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, skin carcinoma, mammary cancer, ovarian cancer, cerebral tumor, prostate cancer, head and neck scale carcinoma, laryngocarcinoma, carcinoma of the pancreas, retinoblastoma cell cancer, children liver parent cell cancer, liver cancer, melanoma, large bowel cancer, adenocarcinoma of colon, glioma, esophagus cancer, nasopharyngeal carcinoma, cerebral glioma, cancer of the stomach, lung cancer, kidney, bladder cancer, thyroid carcinoma.

Embodiment

In order to understand the present invention, further illustrate the present invention with embodiment below, but do not limit the present invention.

embodiment 1 dimethylamine has a smile on one's face the preparation of lactone fumarate

To in the 250mL round-bottomed flask being equipped with mechanical stirring, thermometer, reflux condensing tube, add fumaric acid (1.98g, 17mmol), ethyl acetate (2.5 mL), stir, be heated to 77 DEG C; Dimethylin being had a smile on one's face lactone (5.0g, 17mmol) mixes with ethyl acetate (15 mL), drops in the middle of reaction, vigorous stirring; After dropwising, reaction solution was in 77 DEG C of insulations 3 hours; Stop heating, under whipped state, be naturally down to room temperature, filter, ethyl acetate is washed, and vacuum-drying 24 hours, namely obtains formula (I) compound, white solid 6.3g, yield 90%.

Prepare the data of formula (I) compound:

Molecular formula: C ₂₁h ₃₁nO ₇

Molecular weight: 409

Proterties: white solid powder

Elemental analysis data:

Element	Calculated value/%	Test value/%
			C	61.60	61.41
H	7.63	7.37
			N	3.42	3.54

Nuclear magnetic resonance data (NMR):

¹H NMR (DMSO, 500 MHz)6.58 (s, 2H), 3.80 (t , J = 10.3 Hz, 1H ), 2.64(s, 3H), 2.49-2.53 (m, 3H), 2.26-2.27 (m, 1H), 2.23 (s, 6H), 1.96-2.10 (m, 6H),1.60 (s, 3H), 1.57-1.59 (m, 2H), 1.23-1.25 (m, 1H), 1.15 (s, 3H);

¹³C NMR(DMSO, 125 MHz)177.8, 167.6(2C), 135.2(2C), 133.7, 131.4, 83.4, 80.31, 58.0, 57.1, 51.7, 45.2(2C), 43.6, 41.0, 35.3, 30.2, 27.0, 24.2, 23.2.

High resolution mass spectrum data (HRMS): [C ₁₇h ₂₇nO ₃+ H ⁺]: calculated value, 294.2064; Test value, 294.2067.

embodiment 2 dimethylamine have a smile on one's face lactone fumarate pharmacological action

Various cancer cells is made into 2 × 10 ⁵/ mL cell suspension, add in 24 orifice plate round bottom Tissue Culture Plates, add test compounds respectively, every test concentrations 5 hole, put 37 degree, 5% carbonic acid gas saturated humidity regulates lower cultivation 18 hours, records absorbancy and refers to, calculate the restraining effect of the compounds of this invention to test cancer cells with mtt assay at enzyme connection detector 570nm wavelength.

Table 1 formula I compound is to the restraining effect of various cancer cells

Clone	Formula I compound
		HL-60	31.5
K562	22.3
		MCF-7	19.5
CNE-1	26.3
		CNE-2	26.5
SW620	33.4
		A549	28.3
HepG-2	17.7
		Ec9706	23.2
SGC7901	14.7
		SW1116	37.1
A498	24.1
		ASPC-1	31.5
HT-29	19.2
		HeLa	29.4
GL15	45.2
		B16F1	28.3
T24	32.4
		SKOV3	25.5
SW579	42.3
		PC-3	33.4

HL-60, K562, MCF-7, CNE-1, CNE-2 in table 1, SW620, A549, HepG2, Ec9706, SGC7901, SW1116, A498, ASPC-1, HT-29, HeLa, GL15, B16F1, T24, SKOV3, SW579, PC-3, represent acute myeloid leukemia respectively, chronic myelogenous leukemia, mammary cancer, nasopharyngeal carcinoma, colorectal carcinoma, lung cancer, liver cancer, the esophageal carcinoma, cancer of the stomach, colorectal carcinoma, carcinoma of the pancreas, prostate cancer, colorectal carcinoma, cervical cancer, neuroblastoma, melanoma, bladder cancer, ovarian cancer, thyroid tumor, prostate cancer.

embodiment 3 formula I compound compares with the stability of formula II compound

1. high temperature test

Get formula I compound and formula II compound is put in open container, in the thermostat container of 60 DEG C, place 10 days, in sampling in 0 day, 5 days, 10 days, observe proterties, measure content.

Table 2 high temperature test result (60 DEG C)

2. high wet test

Get formula I compound and formula II compound is put in open container, be placed on relative humidity 90 ± 5%(saltpetre saturated solution) encloses container in, place 10 days, in 0 day, 5 days, 10 days sampling, observe proterties, measure content.

Table 3 high humidity test-results (90 ± 5%)

Result shows: no matter under high temperature or super-humid conditions, formula I compound is all more stable than formula II compound.

embodiment 4 formula I compound draws moist comparison with formula II compound

Table 4 draws moist comparison

	Formula I compound	Formula II compound
			Draw moist	0.5%	15.6%

Result shows: drawing of formula I compound is moist moist lower than drawing of (II) compound.

Purposes of the present invention and method are described by specific embodiment.Those skilled in the art can use for reference the links such as content appropriate change raw material of the present invention, processing condition and realize other object corresponding, its relevant change does not all depart from content of the present invention, all similar replacements and change will become apparent to those skilled in the art that and be all deemed to be included within scope of the present invention.

Claims

1. dimethyl amine has a smile on one's face the form of fumarate of lactone, formula I compound.

2. (I) is being used for the treatment of the purposes in cancer, and described cancer comprises acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, skin carcinoma, mammary cancer, ovarian cancer, cerebral tumor, prostate cancer, head and neck scale carcinoma, laryngocarcinoma, carcinoma of the pancreas, retinoblastoma cell cancer, children liver parent cell cancer, liver cancer, melanoma, large bowel cancer, adenocarcinoma of colon, glioma, esophagus cancer, nasopharyngeal carcinoma, cerebral glioma, cancer of the stomach, lung cancer, kidney, bladder cancer, thyroid carcinoma.